Publications by authors named "D Castellano"

Claim this Profile
N
Nivolumab plus docetaxel versus placebo plus docetaxel for androgen receptor pathway inhibitor-pretreated and chemotherapy-naive metastatic castration-resistant prostate cancer (CheckMate 7DX): a double-blind, randomised, phase 3 trial.
Karim Fizazi, Fred Saad, Teresa Alonso-Gordoa, Bogdan Żurawski, Philippe Barthélémy, Daniel Castellano

Lancet Oncol· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer.
Thomas Powles, Ariel G Kann, Daniel Castellano, Marine Gross-Goupil, Hiroyuki Nishiyama

N Engl J Med· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chromosomal instability in circulating tumor cells and cabazitaxel resistance in metastatic castration-resistant prostate cancer.
Ossian Longoria, Jan Rekowski, Santosh Gupta, Nick Beije, Klaus Pantel, Daniel Castellano

JCI Insight· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Age-related Efficacy and Safety of Darolutamide Plus Androgen-deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-sensitive Prostate Cancer: A Subgroup Analysis of the Phase 3 ARASENS Trial.
Joan Carles, Bertrand Tombal, Maha Hussain, Fred Saad, Karim Fizazi, Daniel Castellano

Eur Urol Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transcription start sites experience a high influx of heritable variants fueled by early development.
Miguel Cortés Guzmán, David Castellano, Clàudia Serrano Colomé, Vladimir Seplyarskiy, Donate Weghorn

Nat Commun· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis